Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    11-January-2001      
Issue 11 Next Update - 14:00 UTC 08:00 EST    12-January-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Proceed To Article In Today's Vidyya
incubated baby
A standard therapy for the lungs of newborn babies is not effective and may be harmful.

Proceed To Article FDA Approves Femara As First-Line Therapy For Advanced Breast Cancer
The FDA today approved a new indication for the breast cancer drug, Femara (letrozole) as a first-line treatment for postmenopausal women with hormone receptor positive or hormone receptor unknown, advanced or metastatic breast cancer. Femara, an aromatase inhibitor, was approved for treatment of advanced breast cancer in 1997 in women whose cancer had not responded to antiestrogen drugs. More...

Proceed To Article Newborn Lung Treatment Poses Risk Of Intestinal Perforation
A treatment commonly prescribed to reduce the risk of chronic lung disease in extremely premature infants does not reduce the risk of death or chronic lung disease in these infants and may increase the risk for perforation of the intestines, according to a study by the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network. More...

Proceed To Article Update: Ebola In Uganda; Cholera In South Africa
Vidyya keeps a close eye on any world wide disease outbreaks. Since last fall we have kept our readers up-to-date on the Ebola epidemic in Uganda. As the cholera epidemic in South Africa worsens, it is our mission to follow and report on any news as it is released. Get information on the current situation in both countries in today's issue. More...

Proceed To Article FDA Panel Recommends Approval Of Cancidas®, An Investigational Antifungal Drug
The Antiviral Advisory Committee of the U.S. Food and Drug Administration today unanimously recommended approval of Cancidas® (caspofungin acetate), an investigational intravenous antifungal medicine, for the treatment of invasive aspergillosis in patients who did not respond to or were intolerant of other antifungal therapies. More...

Proceed To Article

Molecular And Immunologic Approaches To The Diagnosis And Treatment Of Systemic Mycoses
There may be a new drug approval soon for serious mycotic infections. Learn more about the infections, how they are diagnosed and the unfortunate dearth of available, effective treatment. You'll learn information from the NIAID, such as the mainstay of diagnosis of systemic fungal disease and more. More...

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.